ABOUT NMSG

Nordic Myeloma Study Group (NMSG) was established in 1987 by Nordic hematologists with a special interest in clinical myeloma research.

NMSG is an independent Nordic organization of research, active MDs and Norwegian, Swedish, Icelandic, Finnish, Estonian, Lithuanian, and Danish clinics / hospitals who conduct clinical myeloma research. About 60 hematological clinics / hospitals - among these 25 university hospitals in these countries are a part of the NMSG.

 

The vision of NMSG is to ensure optimal evidence-based treatment of all myeloma patients in the Nordic countries through e.g. clinical and controlled studies with associated basic research on the disease and its biology.

 

NMSG holds biannual plenary meetings with a scientific, educational and organizational agenda. All NMSG members may participate in the plenary meetings. NMSG sponsors are invited to participate in the plenary meetings.

The Executive Board consists of 15 members: 3 members from Norway, Sweden, Denmark and Finland and 1 member Iceland, Estonia and Lithuania.

Organization.jpg

Working Groups

The NMSG has five Working Groups including:

· Clinical trial group – Headed by Fredrik Schjesvold

· Translational Research Group – Headed by Niels Abildgaard

· Real-World Data Group – Headed by Cecilie Hveding Blimark

· Flow Group – Headed by Mona Fenstad

· Pro and QoL Group – Headed by Lene Kongsgaard

Click on the group name for more information.

Executive Board

The Executive Board consists of 15 members: 3 members from Norway, Sweden, Denmark and Finland and 1 member Iceland, Estonia and Lithuania.

Besides the board, Nmsg also has 27 NMSG coordinators who coordinating clinical researchers divided between the regional hospital regions with 6 regional coordinators in Norway, 9 in Sweden, 1 in Iceland, 6 in Denmark and 5 in Finland.

At present (2018), NMSG members are made up of 368 clinical researchers and MDs with an interest in myeloma.

Supporters

Grants
NCU.jpg
NTA.jpg
Sponsors
abbvie.JPG
Amgen.JPG
Binding Site.JPG
Celgene_edited.jpg
GSK.JPG
Janssen.JPG
Karyopharm.JPG
Takeda.JPG
Sanofi.JPG